Stratification Analysis by AI Group on the Chance of a Prevalent Vertebral Fracture With Covariate Adjustment After Propensity Score Matching
| AI naïve group (n = 240) | AI treated group (n = 240) | |||||
| Descriptive statistics: Morphometric VF | Descriptive statistics: Morphometric VF | |||||
| Characteristic | Absence (n = 193) (80.4%) | Presence (n =47) (19.6%) | OR (95% CI) | Absence (n = 176) (73.3%) | Presence (n = 64) (26.7%) | OR (95% CI) |
| Age (years), mean ± SD | 64.9 ± 7.9 | 69.5 ± 7.4 | 1.08 (1.03–1.13) | 65.4 ± 7.3 | 69.5 ± 7.2 | 1.09 (1.04–1.15) |
| Previous fractures, n (%) | ||||||
| No | 162 (84.4) | 30 (15.6) | 1 | 144 (80.9) | 34 (19.1) | 1 |
| Yes | 31 (64.6) | 17 (35.4) | 3.2 (1.47–6.98) | 32 (51.6) | 30 (48.4) | 5.26 (2.63–10.87) |
| Total hip BMD (g/cm2), mean ± SD | 0.84 ± 0.11 | 0.76 ± 0.1 | 0.01 (0–0.32) | 0.81 ± 0.09 | 0.81 ± 0.12 | 3.02 (0.11–91.37) |
| Body composition, n (%) | ||||||
| Group A, LBM− and FBM− | 67 (72.8) | 25 (27.2) | 1 | 69 (80.2) | 17 (19.8) | 1 |
| Group B, LBM− and FBM+ | 26 (83.9) | 5 (16.1) | 0.54 (0.16–1.56) | 16 (51.6) | 15 (48.4) | 4.81 (1.82–13.21) |
| Group C, LBM+ and FBM− | 28 (84.8) | 5 (15.2) | 0.63 (0.19–1.89) | 18 (64.3) | 10 (35.7) | 2.68 (0.97–7.36) |
| Group D, LBM+ and FBM+ | 72 (85.7) | 12 (14.3) | 0.62 (0.26–1.45) | 73 (76.8) | 22 (23.2) | 0.83 (0.37–1.88) |
| AI naïve group (n = 240) | AI treated group (n = 240) | |||||
| Descriptive statistics: Morphometric VF | Descriptive statistics: Morphometric VF | |||||
| Characteristic | Absence (n = 193) (80.4%) | Presence (n =47) (19.6%) | OR (95% CI) | Absence (n = 176) (73.3%) | Presence (n = 64) (26.7%) | OR (95% CI) |
| Age (years), mean ± SD | 64.9 ± 7.9 | 69.5 ± 7.4 | 1.08 (1.03–1.13) | 65.4 ± 7.3 | 69.5 ± 7.2 | 1.09 (1.04–1.15) |
| Previous fractures, n (%) | ||||||
| No | 162 (84.4) | 30 (15.6) | 1 | 144 (80.9) | 34 (19.1) | 1 |
| Yes | 31 (64.6) | 17 (35.4) | 3.2 (1.47–6.98) | 32 (51.6) | 30 (48.4) | 5.26 (2.63–10.87) |
| Total hip BMD (g/cm2), mean ± SD | 0.84 ± 0.11 | 0.76 ± 0.1 | 0.01 (0–0.32) | 0.81 ± 0.09 | 0.81 ± 0.12 | 3.02 (0.11–91.37) |
| Body composition, n (%) | ||||||
| Group A, LBM− and FBM− | 67 (72.8) | 25 (27.2) | 1 | 69 (80.2) | 17 (19.8) | 1 |
| Group B, LBM− and FBM+ | 26 (83.9) | 5 (16.1) | 0.54 (0.16–1.56) | 16 (51.6) | 15 (48.4) | 4.81 (1.82–13.21) |
| Group C, LBM+ and FBM− | 28 (84.8) | 5 (15.2) | 0.63 (0.19–1.89) | 18 (64.3) | 10 (35.7) | 2.68 (0.97–7.36) |
| Group D, LBM+ and FBM+ | 72 (85.7) | 12 (14.3) | 0.62 (0.26–1.45) | 73 (76.8) | 22 (23.2) | 0.83 (0.37–1.88) |
AI = aromatase inhibitor; BMD = bone mineral density; FBM− = fat body mass < median value; FBM+ = fat body mass ≥ median value; LBM+ = lean body mass ≥ median value; LMB− = lean body mass < median value; VF = vertebral fractures.
Stratification Analysis by AI Group on the Chance of a Prevalent Vertebral Fracture With Covariate Adjustment After Propensity Score Matching
| AI naïve group (n = 240) | AI treated group (n = 240) | |||||
| Descriptive statistics: Morphometric VF | Descriptive statistics: Morphometric VF | |||||
| Characteristic | Absence (n = 193) (80.4%) | Presence (n =47) (19.6%) | OR (95% CI) | Absence (n = 176) (73.3%) | Presence (n = 64) (26.7%) | OR (95% CI) |
| Age (years), mean ± SD | 64.9 ± 7.9 | 69.5 ± 7.4 | 1.08 (1.03–1.13) | 65.4 ± 7.3 | 69.5 ± 7.2 | 1.09 (1.04–1.15) |
| Previous fractures, n (%) | ||||||
| No | 162 (84.4) | 30 (15.6) | 1 | 144 (80.9) | 34 (19.1) | 1 |
| Yes | 31 (64.6) | 17 (35.4) | 3.2 (1.47–6.98) | 32 (51.6) | 30 (48.4) | 5.26 (2.63–10.87) |
| Total hip BMD (g/cm2), mean ± SD | 0.84 ± 0.11 | 0.76 ± 0.1 | 0.01 (0–0.32) | 0.81 ± 0.09 | 0.81 ± 0.12 | 3.02 (0.11–91.37) |
| Body composition, n (%) | ||||||
| Group A, LBM− and FBM− | 67 (72.8) | 25 (27.2) | 1 | 69 (80.2) | 17 (19.8) | 1 |
| Group B, LBM− and FBM+ | 26 (83.9) | 5 (16.1) | 0.54 (0.16–1.56) | 16 (51.6) | 15 (48.4) | 4.81 (1.82–13.21) |
| Group C, LBM+ and FBM− | 28 (84.8) | 5 (15.2) | 0.63 (0.19–1.89) | 18 (64.3) | 10 (35.7) | 2.68 (0.97–7.36) |
| Group D, LBM+ and FBM+ | 72 (85.7) | 12 (14.3) | 0.62 (0.26–1.45) | 73 (76.8) | 22 (23.2) | 0.83 (0.37–1.88) |
| AI naïve group (n = 240) | AI treated group (n = 240) | |||||
| Descriptive statistics: Morphometric VF | Descriptive statistics: Morphometric VF | |||||
| Characteristic | Absence (n = 193) (80.4%) | Presence (n =47) (19.6%) | OR (95% CI) | Absence (n = 176) (73.3%) | Presence (n = 64) (26.7%) | OR (95% CI) |
| Age (years), mean ± SD | 64.9 ± 7.9 | 69.5 ± 7.4 | 1.08 (1.03–1.13) | 65.4 ± 7.3 | 69.5 ± 7.2 | 1.09 (1.04–1.15) |
| Previous fractures, n (%) | ||||||
| No | 162 (84.4) | 30 (15.6) | 1 | 144 (80.9) | 34 (19.1) | 1 |
| Yes | 31 (64.6) | 17 (35.4) | 3.2 (1.47–6.98) | 32 (51.6) | 30 (48.4) | 5.26 (2.63–10.87) |
| Total hip BMD (g/cm2), mean ± SD | 0.84 ± 0.11 | 0.76 ± 0.1 | 0.01 (0–0.32) | 0.81 ± 0.09 | 0.81 ± 0.12 | 3.02 (0.11–91.37) |
| Body composition, n (%) | ||||||
| Group A, LBM− and FBM− | 67 (72.8) | 25 (27.2) | 1 | 69 (80.2) | 17 (19.8) | 1 |
| Group B, LBM− and FBM+ | 26 (83.9) | 5 (16.1) | 0.54 (0.16–1.56) | 16 (51.6) | 15 (48.4) | 4.81 (1.82–13.21) |
| Group C, LBM+ and FBM− | 28 (84.8) | 5 (15.2) | 0.63 (0.19–1.89) | 18 (64.3) | 10 (35.7) | 2.68 (0.97–7.36) |
| Group D, LBM+ and FBM+ | 72 (85.7) | 12 (14.3) | 0.62 (0.26–1.45) | 73 (76.8) | 22 (23.2) | 0.83 (0.37–1.88) |
AI = aromatase inhibitor; BMD = bone mineral density; FBM− = fat body mass < median value; FBM+ = fat body mass ≥ median value; LBM+ = lean body mass ≥ median value; LMB− = lean body mass < median value; VF = vertebral fractures.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
